Benefit–risk assessment in a post‐market setting: a case study integrating real‐life experience into benefit–risk methodology
暂无分享,去创建一个
Nan Wang | Davide Luciani | Ioanna Tzoulaki | Ed Waddingham | Alain Micaleff | Deborah Ashby | Juhaeri Juhaeri | Richard Nixon | Kimberley Hockley | I. Tzoulaki | R. Nixon | D. Ashby | T. Staa | C. E. Hallgreen | J. Juhaeri | S. Hobbiger | S. Mt-Isa | Kimberley Hockley | Gerald Downey | R. Hermann | Ruth Peters | A. Micaleff | I. Hirsch | D. Luciani | L. Wise | Andrew Thomson | Richard Hermann | Ian Hirsch | Christine E. Hallgreen | Hendrika A. Ham | Shahrul Mt‐Isa | Simon Ashworth | Steve Hobbiger | Tjeerd P. Staa | Gerald Downey | Marilyn Metcalf | Jeremiah Mwangi | Ruth Peters | Isabelle Stoeckert | Lesley Wise | Andrew J. Thomson | S. Ashworth | M. Metcalf | Nan Wang | Ed Waddingham | H. A. Ham | I. Stoeckert | Jeremiah Mwangi | Christine E. Hallgreen
[1] A. Culyer. Value Tree Analysis , 2014 .
[2] W. Feng,et al. Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs , 2012, PharmacoEconomics.
[3] L. Kalra,et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.
[4] B S Levitan,et al. Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines , 2011, Clinical pharmacology and therapeutics.
[5] Z. J. Lipowski. Letter: Psychosomatic medicine. , 1974, Lancet.
[6] L K Gottlieb,et al. Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice? , 1994 .
[7] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[8] The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1991, The New England journal of medicine.
[9] L. Phillips,et al. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies , 2014, Pharmacoepidemiology and drug safety.
[10] M Gent,et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.
[11] J. Caro,et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[12] B. Fasolo,et al. Modelling the risk-benefit impact of H1N1 influenza vaccines. , 2013, European journal of public health.
[13] Risto Lahdelma,et al. SMAA - Stochastic multiobjective acceptability analysis , 1998, Eur. J. Oper. Res..
[14] W. Feng,et al. Treatment Interruptions and Non-Adherence with Imatinib Mesylate and Healthcare Costs A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia , 2007 .
[15] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[16] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[17] Mark Crowther,et al. Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.
[18] Palle Petersen,et al. PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.
[19] Munir Pirmohamed,et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.
[20] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[21] S M Nazarian,et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.
[22] Yuchiao Chang,et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.
[23] H. Billett,et al. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. , 2009, The American journal of geriatric pharmacotherapy.
[24] E. Hylek,et al. Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.
[25] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[26] S. Yusuf,et al. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.
[27] J. Figueira,et al. A survey on stochastic multicriteria acceptability analysis methods , 2008 .